New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and ...

Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial. The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination ...

Kineta, Inc. (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that its ...

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in ...

Wellcome Sanger Institute spin-out Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision ...

a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Phanes Therapeutics, Inc. is a clinical stage biotech company focused on innovative drug discovery and development in oncology. Currently ...

Winston, Jennifer V. Obligacion, Nastaran Salehi Marzijarani, Zhijian Liu, Feng Peng, David J. Lamberto, and Xiaodong Bu, Merck, Rahway NJ. “Greener Manufacturing of STING agonist (MK-1454) featuring ...

ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that it has entered into a ...

(tradename of Merck & Co., Inc., Rahway, NJ, USA). Pursuant to the deal, Evaxion has granted MSD an option to exclusively license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 ...

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win ® platform, today announced two ...

today announced that it has entered into an option and license agreement with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA) for two preclinical vaccine candidates. The agreement expands the ...